Acelyrin Affibody and Inmagene Biopharma presents phase 2 trial of Izokibep in patients with psoriatic arthritis at EULAR congress

Acelyrin Affibody and Inmagene Biopharma presents phase 2 trial of Izokibep in patients with psoriatic arthritis at EULAR congress

By, Admin 6 June 2022

Acelyrin, Inc., Affibody AB and Inmagene Biopharmaceuticals announced data from a 16-week, global, phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) presented by Frank Behrens, MD, Associate Professor of Medicine, head of rheumatology clinical research, University Hospital & deputy director Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Goethe-University Frankfurt, Germany and a founding member of the Group of Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), during a podium session at the 2022 European Alliance of Associations for Rheumatology (EULAR) Congress in Copenhagen. The randomized double-blind, placebo-controlled, phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks (Q2W) or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA. The global study assessed various endpoints at 16 weeks including the American College of Rheumatology (ACR) response, the Leeds Enthesitis Index (LEI), the Psoriasis Area and Severity Index (PASI) score and Quality of Life via the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!